Adjuvant chemotherapy for stage II nonseminomatous XXXX .

@entity1 @entity101 @entity28 @entity1755 @entity5 @entity900 @entity189 @entity1732 @entity5713
BACKGROUND: The success of chemotherapy for Stage III @entity189 warranted its use as an adjuvant therapy for @entity5 . The current report reflects the adjuvant program begun at the University of Minnesota using four courses of @entity5713 , @entity1732 , and @entity900 (VBP) before the onset of the @entity5 Intergroup Study using two courses of chemotherapies. METHODS: A review of 78 @entity1 with Stage II nonseminomatous germ cell @entity5 treated between 1972 and 1986 defined three groups: 19 @entity1 treated between 1972 and 1979 with various adjuvant chemotherapies (termed "other"), 37 @entity1 treated from 1975 to 1986 with VBP adjuvant chemotherapy, and 21 @entity1 who received no therapy during the same era of VBP. The latter group was not offered adjuvant chemotherapy at other institutions or declined therapy. RESULTS: Nineteen @entity1 received adjuvant chemotherapy before the @entity900 era. Their survival rate was 42%, including two @entity1 treated with @entity900 -based chemotherapy for recurrence. In the group of 21 @entity1 who did not receive adjuvant therapy, 14 (66.7%) survived. Of these, five had no recurrence and nine were treated for recurrence. In a third group, adjuvant VBP therapy was given to 37 @entity1 , 32 of whom received four full courses. There have been no recurrences, and 36 (97.3%) remain alive; one @entity28 @entity1 with @entity101 died of a @entity1755 12.9 years after the retroperitoneal lymph node dissection. Nodal involvement was more extensive in the VBP group. CONCLUSION: Four courses of VBP adjuvant chemotherapy for pathologic @entity5 resulted in a 100% cure rate, all @entity1 having been followed up for more than 6 years. Whether two courses are as adequate remains to be determined when long-term follow-up is reported.
